Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Q4 2023 Earnings Presentation
23 slides from Nykode Therapeutics Asa's earnings presentation, Feb 28, 2024
Slide 1: Q4 2023 Results Presentation
Q4 2023 Results Presentation February 28, 2024
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Today's presenters from Nykode management
Today’s presenters from Nykode management International management team with solid drug development experience MICHAEL ENGSIG AGNETE FREDRIKSEN HARALD GURVIN KLAUS EDVARDSEN Chief Executive Officer Chief Business Officer & Chief Financial Officer Chief Development Officer Co-founder Nykode Therapeut
Slide 4: Q4 2023 Highlights
Q4 2023 Highlights • Expanded oncology pipeline with the addition of NYK011 aimed at preventing and treating colorectal cancer including Nykode's proprietary next generation technology • Presented preclinical data demonstrating Nykode’s APC targeted technology yields superior immune response, whethe
Slide 5: Private placement highlights
Private placement highlights • Raised NOK 505 million ($45m) • Offering significantly oversubscribed, demonstrating robust interest from international life- science specialist investors • Use of Proceeds: • Advance VB10.16 clinical studies, including VB-C-05 in locally advanced cervical cancer • Exp
Slide 6: Rich and diversified pipeline
Rich and diversified pipeline Upcoming Asset Indication Rights Preclinical Phase 1 Phase 2 Phase 3 Catalyst Oncology 1 Initiate trial HPV16+ cervical cancer C-02, C-04 (Q1 2024) 2 Dose level VB10.16 HPV16+ head and neck cancer C-03 recommendation (H2 2024) 2 Off-the-shelf HPV16+ locally advanced Pro
Slide 7: R&D update
R&D update Nykode Therapeutics | Q4 '23 webcast | Non-confidential
Slide 8: Nykode's proprietary technology platform allows APC-targeting to direct immune responses
Nykode’s proprietary technology platform allows APC- targeting to direct immune responses DNA plasmid Targeting unit to attract and bind APCs encoding Ability to tailor the targeting unit enables induction of different immune response Nykode vaccine profiles to specific diseases1 Dimerization unit f
Slide 9: VB10.16: Therapeutic vaccine candidate for HPV16+ cancers
VB10.16: Therapeutic vaccine candidate for HPV16+ cancers Targeting unit Off-the-shelf therapeutic cancer DNA vaccine CCL3L1 against HPV16 induced malignancies HPV16 is the most prevalent oncogenic HPV strain VB10.16 Off-the-shelf vaccine Targeting the cancer-specific full-length HPV16 E7 target
Slide 10: VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC
VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC in ≥2L r/m cervical cancer CPI Monotherapy in r/m CC VB10.16 plus Atezolizumab in Pembrolizumab Cemiplimab in Tisotumab vedotin atezolizumab PD-L1+††† in PD-L1+** PD-L1+ †† (PD-L1 agnostic) ‡ ‡ in PD-L1+ Skyscraper-04, Emp
Slide 11: Maximizing addressable patient populations by diversifying offerings and broadening therapeutic scope
Maximizing addressable patient populations by diversifying offerings and broadening therapeutic scope Building a cancer vaccine franchise following strong clinical validation Validation Today Future Opportunities C-05 Adjuvant Settings Move earlier to expand patient population and Indication Expansi
Slide 12: Creating a portfolio of targeted vaccines for HPV16+ cancers
Creating a portfolio of targeted vaccines for HPV16+ cancers VB10.16 portfolio C-02 C-03 C-04 C-05 r/m head and neck cancer r/m Cervical Cancer, ≥2L r/m Cervical Cancer, Locally Advanced Cervical Indication (HNSCC), PD-L1+, 2L Cancer (LACC) PD-L1+, 1L Up to 9 mg in combination 3 mg in combination wi
Slide 13: NYK011 aims at addressing patients ranging from high-risk pre-cancerous polyps to colorectal cancer
NYK011 aims at addressing patients ranging from high-risk pre- cancerous polyps to colorectal cancer • Colorectal cancer develops from premalignant polyps on the colon or rectum’s mucosal surface • Disease development and screening programs represent an Broad patient population opportunity to identi
Slide 14: Potential first-in-class program including Nykode's 4th module 2nd generation technology
Potential first-in-class program including Nykode’s 4th module 2nd generation technology • NYK011 is a potential first-in-class oncology vaccine program based on careful selection and novel combination of tumor-associated antigens (TAA) • Leverages Nykode’s expertise to elicit strong and broad CD8 T
Slide 15: APC targeting technology can leverage mRNA vaccines and presents opportunity for platform expansion
Nykode’s APC targeting technology can leverage mRNA vaccines and presents opportunity for platform expansion Targeted delivery via APCs using Nykode’s technology has been shown to induce broader and stronger CD8+ immune responses vs. existing ‘antigen-alone’ approaches. Preclinical studies have demo
Slide 16: Superior immunogenicity using Nykode's APC-targeted mRNA-LNP vaccines
Superior immunogenicity using Nykode’s APC-targeted mRNA- LNP vaccines Stronger T cell responses to a wider variety of T cell epitopes Prime vaccination only (D14) Prime + boost vaccination (D28) ✱ p=0.0473 25000 ✱ p=0.0192 2000 N01 N01 N02 N02 N03 N03 N04 N04 20000 N05 N05 1500 N06 N06 N07 N07 N08
Slide 17: DNA vaccination induces long-lasting efficacy post treatment in a diabetes model
DNA vaccination with Vaccibody induces long-lasting efficacy post treatment in a diabetes model Dosing once weekly until week 16 Week 16 of treatment Wk 0 Wk 1 Wk2 Wk 3 Wk 4 Wk 5……… Weekly monitoring Remove treatment Still ongoing 9 wk old mice NOD DIABETES MODEL (ONGOING STUDY) VB vaccine Incidence
Slide 18: Q4 2023 Financial Results
Q4 2023 Financial Results
Slide 19: Income Statement
Income Statement Revenue from contracts with customers Amounts in USD ‘000 Q4 2023 Q4 2022 FY 2023 FY 2022 • R&D activities under Genentech and Regeneron Revenue from contracts with customers 2,191 2,690 12,902 7,168 agreements Other income 89 610 421 1,861 • $2.0m (Q4 2023) and $12.0m (FY 2023) und
Slide 20: Balance Sheet
Balance Sheet Cash and cash equivalents Amounts in USD ‘000 31/12/2023 31/12/2022 • Strong cash position of $162.6m at December 31, ASSETS 2023 Non-current assets Other non-current receivables Property, plant and equipment 4,413 3,517 Right-of-use assets 6,104 6,009 • Increase due to payment to Norw
Slide 21: Balance Sheet - contd.
Balance Sheet - contd. Amounts in USD ’000 31/12/2023 31/12/2022 Equity EQUITY AND LIABILITIES • Total equity of $171m as per December 31, 2023 Equity Share capital 367 338 • Equity ratio of 82% Share premium 128,986 83,318 Other capital reserves 15,395 11,694 Other components of equity (3,048) (3,0
Slide 22: Upcoming milestones
Upcoming milestones Q1 ‘24 VB10.16 Initiate potentially registrational VB-C-04 trial in the U.S. in patients with Cervical Cancer recurrent/metastatic disease and PD-L1 positive tumors VB10.16 Q1 ‘24 Cervical Cancer Updated survival data from VB-C-02 Phase 2 trial Oncology H2 ‘24 VB10.16 Recommended
Slide 23: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Alexandra Deschner Head of Investor Relations IR@nykode.com Nykode Therapeutics | Q4 '23 webcast | Non-confidential